My PCR
Create Account
Logo PCR

20 May 2026

Monotherapy vs. DAPT: striking the balance between ischemia and bleeding

Session comprising selected EuroPCR 2026 abstract submissions

Moderators: S. Schupke, A. Van't Hof
Speakers: J. Cheng, P. Tartuce, G. Pompei, A. Hakeem, D. H. Gim

Summary

This session examines the balance between ischemic and bleeding risks by comparing monotherapy regimens and dual antiplatelet therapy (DAPT) following PCI. Key topics include clopidogrel versus aspirin monotherapy, aspirin discontinuation timing after ACS, and the impact of P2Y12 adherence on clinical outcomes in high-risk and oral anticoagulated patients.

Presentations available when logged in:

  • Clopidogrel vs. aspirin monotherapy: beyond one year after PCI in high-risk patients
  • Immediate aspirin discontinuation after PCI for ACS: reconstructed IPD of NEO-MINDSET and STOPDAPT-3
  • Clopidogrel vs. aspirin-based DAT after PCI in OAC patients: a post-hoc analysis of PERSEO registry
  • TADCLOT trial: impact of strict P2Y12 adherence on early MACE and stent thrombosis
  • Clopidogrel vs. aspirin monotherapy according to atherothrombotic risk profile
Related Content
Sirolimus-Eluting Balloon vs. Repeat Drug-Eluting Stent or Balloon Angioplasty for Coronary... Lead management during tricuspid interventions TAVI versus SAVR in aortic stenosis, is the debate still relevant in 2026?
Recommended for you
Register for the PCR Fundamentals Course London 2026 CHIP-BCIS3: Left ventricular unloading in high-risk PCI PCR Rio Valves 2026 : Call for Submissions is now open